Biosimilar competition for Amgen’s blockbuster rheumatoid arthritis drug Enbrel is lurking in the background, but the biotech may have found a way to help…

Pharma’s top U.S. execs haven’t been shy about expressing their desire for tax reform—and now, they’re taking those wishes directly to Congress.

Pharma execs and boards essentially pressed pause on dealmaking as 2016 came to a close, with uncertainties about the U.S. presidential election—and a Donald…

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…

Activist investors have moved in on Bristol-Myers Squibb, including Carl Icahn, who has a long history of pushing drugmakers to put themselves on the block.

This year’s flu vaccine is working for almost half of recipients, the CDC says in an update on what it’s calling a “moderate” season.

J&J is the most admired pharma company, according to Fortune's annual corporate poll, for the fourth year in a row and comes in at No. 13 among all…

​​​​​​​Gilead might not enjoy suffering its recent, severe hep C revenue downfall, but according to one analyst, the rest of biopharma stands to benefit from…

Pfizer scored new Crohn’s data that could give its Remicade biosimilar, Inflectra, more oomph for its market-share fight, one of the first U.S. head-to-heads…

Pharma